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Abstract
Over the last 50 years, there has been a steady improvement in the treatment outcome of acute myeloid leukemia
(AML). However, median survival in the elderly is still poor due to intolerance to intensive chemotherapy and higher
numbers of patients with adverse cytogenetics. Fadraciclib (CYC065), a novel cyclin-dependent kinase (CDK) 2/9
inhibitor, has preclinical efficacy in AML. In AML cell lines, myeloid cell leukemia 1 (MCL-1) was downregulated
following treatment with fadraciclib, resulting in a rapid induction of apoptosis. In addition, RNA polymerase II
(RNAPII)-driven transcription was suppressed, rendering a global gene suppression. Rapid induction of apoptosis was
observed in primary AML cells after treatment with fadraciclib for 6–8 h. Twenty-four hours continuous treatment
further increased efficacy of fadraciclib. Although preliminary results showed that AML cell lines harboring KMT2A
rearrangement (KMT2A-r) are more sensitive to fadraciclib, we found that the drug can induce apoptosis and decrease
MCL-1 expression in primary AML cells, regardless of KMT2A status. Importantly, the diversity of genetic mutations
observed in primary AML patient samples was associated with variable response to fadraciclib, confirming the need for
patient stratification to enable a more effective and personalized treatment approach. Synergistic activity was
demonstrated when fadraciclib was combined with the BCL-2 inhibitor venetoclax, or the conventional chemotherapy
agents, cytarabine, or azacitidine, with the combination of fadraciclib and azacitidine having the most favorable
therapeutic window. In summary, these results highlight the potential of fadraciclib as a novel therapeutic approach
for AML.
Introduction
Acute myeloid leukemia (AML) is one of the most
common hematologic malignancies, characterized by
clonal, proliferative, and abnormally or poorly differ-
entiated myeloid cells infiltrating the bone marrow, blood
or extramedullary tissues1–3. Although treatment has
progressed, in some AML patients, particularly the
elderly1,4, outcome is dismal due to the remarkable
genetic complexity5,6, epigenetic alterations7–9, and the
dynamics of the disease10,11. Treatment-related morbid-
ity/mortality and resistance to chemotherapy are major
causes of treatment failure12. However, longer life
expectancy and possibly a cure is achievable if complete
remission (CR) is attained13,14. Therefore, there is sub-
stantial research to improve and personalize therapies,
and lessen treatment toxicity15–18.
Currently, several novel agents acting through distinct
molecular targets, identified in the pathophysiology of
AML, are being investigated alone or combined with
conventional chemotherapy, e.g., FLT3 inhibitors (mid-
ostaurin19, gilteritinib20), IDH1/2 inhibitors (ivosidenib21,
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enasidenib22,23), BCL-2 inhibitor (venetoclax24,25), and
cyclin-dependent kinase (CDK) inhibitors (CDKi; alvoci-
dib26–28, fadraciclib29), which cause cell cycle arrest and
induce apoptosis.
The second generation CDKi fadraciclib is an orally
available 2,6,9-trisubstituted purine analog designed to
selectively inhibit CDK2 and CDK929–31. Direct inhibition
of CDK2 results in cell cycle arrest of abnormally pro-
liferating cells32. The blockade of CDK9 halts RNA
polymerase II (RNAPII) transcriptional activity conse-
quently inducing apoptosis33. Furthermore, CDK9 inhi-
bition downregulates the anti-apoptotic protein myeloid
cell leukemia 1 (MCL-1)34. Fadraciclib has already entered
clinical trials in advanced solid tumors (NCT02552953),
chronic lymphocytic leukemia (CLL) (NCT03739554) and
AML (NCT04017546).
In this study, fadraciclib was assessed for efficacy against
AML cell lines and primary AML samples in vitro either
as a single agent or in combination with venetoclax
(VEN), cytarabine (AraC), or azacitidine (AZA).
Results
Fadraciclib induces apoptosis of AML cell lines and reduces
metabolic activity confirming anti-proliferative effect
IC50 of fadraciclib was established by resazurin reduction
assay at 24, 48, and 72 h. The IC50 of fadraciclib was lower
at 72 h, compared to 24 and 48 h, showing that longer
exposure increased drug potency (Fig. 1A). At 72 h, the IC50
of fadraciclib in OCI-AML3, MOLM-13 and MV4–11 was
approximately 0.44 ± 0.01 µM, 0.25 ± 0.01 µM and 0.52 ±
0.01 µM, respectively. As compared to the IC50, which is
related to anti-proliferative activity, higher fadraciclib doses
were required to induce apoptosis in 50% of cells, repre-
sented by the percentage of annexin V-positive cells
(%annexinV). 0.75, 0.5, and 1 µM of fadraciclib was required
to induce apoptosis in 50% of cells in OCI-AML3, MOLM-
13 and MV4–11, respectively (Fig. 1B, C). This was con-
firmed by a significant concentration-dependent increase in
the percentage of active caspase-3-positive cells (%active
caspase-3; Fig. 1D). Cell cycle analysis at 72 h demonstrated
a significant increase in the percentage of sub G0 (%subG0)
population at concentrations of 0.75 μM, 0.5 μM, and 1 μM
of fadraciclib for OCI-AML3, MOLM-13, and MV4–11,
respectively, with no evidence of cell cycle arrest (Fig. 1E).
However, at 4 h, G1 arrest occurred in OCI-AML3 and
MV4–11, but not MOLM-13 (Supplementary Fig. S1).
Taken together, fadraciclib potently induces apoptosis,
increases the subG0 population, and reduces proliferation as
evidenced by reduced metabolic activity in AML cell lines.
Fadraciclib downregulates MCL-1, resulting in rapid
induction of apoptosis in AML cell lines
AML cell lines were treated with 1 µM fadraciclib, for 4
and 24 h. An inhibitory effect on downstream targets was
demonstrated by immunoblotting (Fig. 2A). Inhibition of
CDK2 and CDK9 was evaluated by phosphorylation levels
at serine 807/serine 811 of retinoblastoma (Rb) and serine
2 of RNAPII, respectively. Rb was not expressed in OCI-
AML3. In MOLM-13, densitometry confirmed a 75%
reduction in Rb levels by 4 h (p < 0.0001) and greater than
99% at 24 h, with a corresponding reduction in the
phosphorylated form (p-Rb). In MV4–11, only a modest
reduction in the levels of Rb and p-Rb at 4 h, with Rb level
returning to baseline and a modest increase in p-Rb
observed at 24 h (Fig. 2A, B). At 4 h, in all cell lines, the
level of RNAPII decreased by approximately 60% with a
corresponding decrease in phosphorylation (Fig. 2A, C);
with similar results at 24 h.
A significant downregulation of MCL-1 occurred at 4 h
in all cell lines and was maintained or further decreased at
24 h (Fig. 2A, D). This induced apoptosis as indicated by
the accumulation of cleaved poly (ADP-ribose)
polymerase-1 (Fig. 2A, E). The function of CDK1 was not
perturbed as observed by an unchanged level of threonine
320 phosphorylated protein phosphatase 1 alpha (Sup-
plementary Fig. S2A, B).
Owing to the impact of fadraciclib on MCL-1 levels,
relevant signaling pathways, controlling MCL-1 were
investigated. Threonine 180/tyrosine 182 phosphorylated
p38 MAPK was markedly increased at 4 h in MOLM-13
(p < 0.0001) and MV4–11 (p < 0.001), and at 24 h in
MOLM-13, but not in OCI-AML3 (Supplementary Fig.
S2A, C). A decrease in threonine 202/tyrosine 204 phos-
phorylated Erk1/2 was also observed at 4 and 24 h (Sup-
plementary Fig. S2A, D). By contrast, serine 473
phosphorylated Akt (Supplementary Fig. S2A, E) and
serine 9 phosphorylated GSK3β (Supplementary Fig. S2A,
F) were not significantly changed.
These results imply that stress response and apoptosis
are potently induced in MOLM-13 and MV4–1135–38,
and the observed downregulation of MCL-1 was unlikely
to be via the proteasome-dependent degradation pathway
modulated by GSK3β39.
Fadraciclib alters cell cycle regulatory gene expression to
induce apoptosis
OCI-AML3, MOLM-13 and MV4–11 were treated with
0.75, 0.5, and 1 µM of fadraciclib, respectively, for 4 and
24 h and the effect on cell cycle regulatory gene expres-
sion investigated. The heatmap depicts fold change of
gene expression as compared with NDC (Fig. 2F). Several
target genes were downregulated following fadraciclib
treatment, including; CDK family, transcription factors,
key protein phosphatases, CDKI, DNA damage response
regulators, anti-apoptotic related, and pro-apoptotic
related genes (Supplementary Figs. S3–S5).
In particular, at 4 h, the expression of CDKs, especially
CDK9, the transcription factor E2F1, and MCL1, were
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Fig. 1 Fadraciclib reduces metabolic activity and causes apoptosis of AML cell lines. A The IC50 of fadraciclib at 24, 48 and 72 h in AML cell
lines using the rezasurin reduction assay. B Representative flow cytometry plots Annexin V/DAPI apoptosis assay for the OCI-AML3 cell line treated
with fadraciclib for 72 h. C Bar charts based on flow cytometry data for the percentage of annexin V-positive cells in AML cell lines treated with
fadraciclib for 72 h. D Representative flow cytometry plots and summary bar charts of the percentage of active caspase-3-positive cells in AML cell
lines treated with fadraciclib for 72 h. E Representative flow cytometry plots and summary bar charts of cell cycle phase using PI staining of AML cell
lines treated with fadraciclib for 72 h. n= 3.Graphs depict mean ± SD (****p < 0.0001). Data were compared using ANOVA.
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Fig. 2 Fadraciclib downregulates MCL-1, resulting in rapid induction of apoptosis in lines treated with 1 µM of fadraciclib for 4 and 24 h.
SH-PTP2 was used as an internal AML cell lines. A Representative Western blot of OCI-AML3, MOLM-13, and MV4-11 cell protein loading control.
B Densitometric analysis of serine 807/serine 811 (S807/S811) phosphorylated and total Rb. C Densitometric analysis of serine 2 (S2) phosphorylated
RNAPII and total RNAPII. D Densitometric analysis of MCL-1. E Densitometric analysis of cleaved poly (ADP-ribose) polymerase-1 (PARP1). F Heatmap
demonstrating fold changes relative to NDC of gene expression of OCI-AML3, MOLM-13, and MV4-11 cell lines treated with 0.75, 0.5, and 1 µM of
fadraciclib, respectively, for 4 and 24 h. G Fold changes of CDK9, MCL1, PPP1R10, and E2F1 gene expression as compared with NDC. n= 3. Graphs
depict mean ± SD (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Data were compared using the Student’s t-test.
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suppressed. PPP1R10 was also significantly down-
regulated (Fig. 2F, G). Effects on gene expression were less
marked at 24 h. Conversely, the DNA damage response
regulator gene CDKN1A, encoding p21Cip1, was upregu-
lated at 24 h, indicating the intrinsic apoptosis pathway40
was activated following fadraciclib treatment (Supple-
mentary Fig. S4B).
Fadraciclib induces apoptosis and decreases MCL-1
expression in primary AML cells, regardless of KMT2A-PTD
status
Published results indicate AML cell lines bearing
KMT2A rearrangements (KMT2A-r) are sensitive to
fadraciclib29. Five primary AML samples harboring
KMT2A-partial tandem duplication (PTD) and five pri-
mary AML samples with KMT2A wild-type (WT) were
tested with fadraciclib as a single agent (Table. 1). All
samples were treated with 0.5 and 1 µM fadraciclib for
24 h, then the drug was washed out and cells were cul-
tured in fresh media for up to 72 h.
At 24, 48, and 72 h time points, fadraciclib treatment
resulted in an increase in apoptosis in both KMT2A-PTD
and KMT2A WT patient samples (Fig. 3A, B). The pro-
portion of apoptotic cells significantly increased over
time. Specifically, at 72 h, a concentration-dependent
maximal increase in %annexinV was observed in
KMT2A-PTD patient samples following treatment with
fadraciclib at 0.5 µM (20.5 ± 9.6%, p= 0.6051) and 1 µM
(79.5 ± 12.9%, p < 0.0001), and in KMT2A WT patient
samples following treatment with fadraciclib at 0.5 µM
(33 ± 14.6%, p= 0.624) and 1 µM (74 ± 26%, p < 0.0001)
compared with NDC (Fig. 3A). Responses were similar in
KMT2A-PTD and KMT2A WT patient samples.
A concentration-dependent increase in %active caspase-
3 was observed in both KMT2A-PTD and KMT2A WT
patient samples following fadraciclib treatment (Fig. 3B).
However, due to genetic heterogeneity of AML samples
(Table. 1), this difference did not reach statistical
significance.
Treatment with fadraciclib resulted in a time- and
concentration-dependent decrease in MCL-1 expression
in both KMT2A-PTD and WT AML samples. Specifically,
at 72 h, a decrease in MCL-1 in KMT2A-PTD patient
samples at 0.5 µM (42.8 ± 20.3%, p= 0.9997) and 1 µM
(5.4 ± 3.2%, p= 0.1852), and in KMT2A WT patient
samples at 0.5 µM (31.2 ± 21.2%, p= 0.9463) and 1 µM
(4 ± 1%, p= 0.1913) following fadraciclib treatment
compared with NDC (Fig. 3C).
Pulsed dosing with fadraciclib in primary AML cells results
in apoptosis and reduces cell viability, but is less effective
than continuous dosing
To determine if pulsed dosing achieved an optimal
response, primary AML cells were treated for up to 8 h
with fadraciclib at a concentration of 1 μM. This resulted
in a significant increase in %annexinV at both 6 and 8 h
(p= 0.023 and p= 0.0411, respectively) and %active
caspase-3 at 6 h (p= 0.0351) as compared with NDC
(Supplementary Fig. S6A, B). As fadraciclib exerts a rapid
effect, we investigated whether a 6-h pulse was as effective
as 24-h continuous treatment at inducing apoptosis.
Fadraciclib showed a higher %active caspase-3 after con-
tinuous treatment compared to the pulsed treatment
(Supplementary Fig. S6C). MCL-1 levels were significantly
reduced after 24-h continuous treatment compared to
both the NDC and the 6-h pulsed treatment (p= 0.0167
and p= 0.0304, respectively; Supplementary Fig. S6D).
Increased apoptosis of primary human AML samples in
combination studies of fadraciclib+ VEN, fadraciclib+
AraC, and fadraciclib+ AZA
For combination studies, six primary AML samples
were selected based on the presence of the most common
favorable (e.g., NPM1) and unfavorable mutations (e.g.,
FLT3-internal tandem duplication (ITD) and KMT2A-
PTD), in order to assess the efficacy of fadraciclib and its
synergistic activity when combined with VEN, AraC, or
AZA, towards these mutations.
Drug combination studies exploit opportunities for
reduced drug resistance, decreased toxicity, and efficacy
improvement41. Based on phase 1 clinical trial data, the
maximum clinically achievable concentration of fadraci-
clib is 6–7 µM when administered as a single agent42. In
this study, much lower fadraciclib concentrations of
0.25 µM (FAD1) and 0.5 µM (FAD2) in combination with
VEN, AraC or AZA were assessed for efficacy against
primary AML cells. The concentrations selected were
based on previous studies: 0.025 µM (VEN1) and 0.5 µM43
(VEN2); 0.01 µM (AraC1) and 0.1 µM44 (AraC2); 0.5 µM45
(AZA1) and 2 µM46 (AZA2), aiming to optimize results
for both sensitive and more therapy-resistant patient
samples. All drug concentrations were within clinically
achievable concentrations (1 µM VEN47, 1 µM AraC48,
and 3–11 µM AZA49). Apoptosis, active caspase-3, cell
cycle analyses, and proliferation assays were performed at
72 h.
In primary AML samples, %annexinV and %active
caspase-3 (Supplementary Figs. S7A–C and S8A–C,
respectively) were not significantly different at low con-
centrations, with any drug combination pair tested. At
high concentrations, a modest increase in %annexinV was
observed; 82.2 ± 16.9% in FAD2+VEN2 combination (as
compared with 55.7 ± 14% in FAD2, p= 0.1059; and
64.6 ± 21.4% in VEN2 alone, p= 0.5166) (Supplementary
Fig. S7A), 81.6 ± 13.4% in FAD2+AraC2 combination (as
compared with 55.7 ± 14% in FAD2, p= 0.1077; and
69.5 ± 22.5% in AraC2 alone, p= 0.8117) (Supplementary
Fig. S7B), and 87.7 ± 12.3% in FAD2+AZA2 combination
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Fig. 3 Fadraciclib induces apoptosis and decreased MCL-1 expression in primary AML cells, regardless of KMT2A-PTD status. All samples
were treated with 0.5 µM or 1 µM of fadraciclib for 24 h, then the drug was washed out and cells were cultured in fresh media for up to 72 h.
A Representative flow cytometry plots and summary bar charts of the percentage of annexin V-positive cells. n= 4–5. B Representative flow
cytometry plots and summary bar charts of the percentage of active caspase-3-positive cells. n= 4–5. C Representative flow cytometry plots and
summary bar charts of the percentage of the MCL-1 level. n= 3. Graphs depict mean ± SD (**p < 0.01, ****p < 0.0001). Data were compared
using ANOVA.
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(as compared with 55.7 ± 14% in FAD2, p= 0.0109; and
70.7 ± 22.8% in AZA2 alone, p= 0.437) (Supplementary
Fig. S7C). Consistently, a modest increase in %active
caspase-3 was observed at high concentrations; 84.3 ±
11.5% in FAD2+VEN2 combination (as compared with
55.6 ± 14% in FAD2, p= 0.0217; and 65.2 ± 17.9% in
VEN2 alone, p= 0.267) (Supplementary Fig. S8A), 86.8 ±
5.9% in FAD2+AraC2 combination (as compared with
55.6 ± 14% in FAD2, p= 0.0143; and 69.3 ± 19.5% in
AraC2 alone, p= 0.4081) (Supplementary Fig. S8B), and
90.7 ± 4% in FAD2+AZA2 combination (as compared
with 55.6 ± 14% in FAD2, p= 0.0006; and 74.4 ± 17.3% in
AZA2 alone, p= 0.3197) (Supplementary Fig. S8C).
Cell cycle analysis revealed %subG0, but no other cell
cycle phase, marginally increased in agreement with the
increase in %annexinV and %active caspase-3 observed in
FAD2+VEN2, FAD2+AraC2 and FAD2+AZA2 com-
bination (Supplementary Fig. S9A–C) as compared with
each single drug treatment. Overall results indicate the
more complex the molecular genetic lesions or com-
plexity of karyotype, the less efficacious the combination
therapy was (Supplementary Table S4).
Fig. 4 A therapeutic window was observed in cell proliferation assays with the combination of fadraciclib and AZA. A Summary bar charts of
flow cytometry data of the percentage of undivided populations of primary AML and D normal hematopoietic patient samples treated with
fadraciclib and/or VEN for 72 h. n= 6/3. B Summary bar charts of flow cytometry data of the percentage of undivided populations of primary AML
and E normal hematopoietic patient samples treated with fadraciclib and/or AraC for 72 h. n= 6/3. C Summary bar charts of flow cytometry data of
the percentage of undivided populations of primary AML and F normal hematopoietic patient samples treated with fadraciclib and/or AZA for 72 h.
n= 6/3. Graphs depict mean ± SD (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Data were compared using ANOVA.
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Fadraciclib alone and low-dose combination therapies
have limited cytotoxicity on normal hematopoietic cells
Fadraciclib alone and in combination with VEN, AraC
and AZA was assessed in normal CD34+ hematopoietic
samples to determine toxicity. Neither fadraciclib alone
nor lower concentration drug combinations exerted a
significant increase in %annexinV, %active caspase-3 or %
subG0 (Supplementary Figs. S7D–F, S8D–F, and S9D–F,
respectively) as compared to NDC. However, as expected,
an increase in %annexinV was observed at high con-
centrations with a corresponding increase in %active
caspase-3 (Supplementary Figs. S7D–F and S8D–F,
respectively).
Fadraciclib+ AZA combination therapy has a therapeutic
window in in vitro cell proliferation assays
Finally, cell proliferation assays using CellTrace Violet
staining were performed. Representative histograms for
AML and normal CD34+ samples are shown (Supple-
mentary Fig. S10). When considering the combination
therapies, none of the low concentration drug combina-
tions resulted in a significant anti-proliferative effect
(increased percentage of undivided population, %Undi-
vided %undivided) compared to either NDC or single
drug therapies in either AML or normal CD34+ samples
(Fig. 4A–F).
However, differences occurred with the high con-
centration drug combinations. Specifically, FAD2+
VEN2, had significant anti-proliferative effects when
compared to VEN2, but might be explained by the effect
of FAD2 (Fig. 4A). This combination had no anti-
proliferative effect on normal CD34+ cells (Fig. 4D).
Although FAD2+AraC2, has significantly increased anti-
proliferative effect as compared to FAD2 in both AML
and normal CD34+ samples, this is fully accounted for by
the known cytotoxic effects of AraC (Fig. 4B, E). For
FAD2+AZA2, the anti-proliferative effect in AML sam-
ples was significantly increased compared to both FAD2
and AZA2 (%Undivided %undivided of 68.7 ± 29.1% for
FAD2+AZA2 compared with 28.5 ± 10.2% in FAD2, p=
0.0004; and 33.5 ± 17% in AZA2, p= 0.0024), as well as
NDC (Fig. 4C), indicating synergism of this combination
with a combination index (CI) of 0.75. No anti-
proliferative effect was demonstrated for this combina-
tion on normal CD34+ cells (Fig. 4F).
These findings indicate a therapeutic window and pro-
vide evidence for further exploration of combination
treatment with fadraciclib and AZA as a promising
treatment approach.
Discussion
Our study evaluated the therapeutic potential of fadra-
ciclib in AML. AML cell lines harboring various genetic
lesions were tested, these include OCI-AML3 (carries
NPM1 and DNMT3AR882C mutations), MOLM-13 (car-
ries FLT3-ITD and KMT2A-MLLT3), and MV4–11 (car-
ries FLT3-ITD and KMT2A-AFF1), aiming to encompass
stratification of major risk profiles according to the Eur-
opean LeukemiaNet recommendations50. Results indicate
MV4–11, harboring adverse prognosis molecular
abnormalities, was less sensitive with the highest IC50
(Fig. 1A) and a higher dose of fadraciclib required to
induce apoptosis (Fig. 1C–E).
Inhibition of CDK2 and CDK9 was evaluated by phos-
phorylation of Rb51,52 and RNAPII53,54. We found the
effects of fadraciclib on Rb were cell line specific (Fig. 2A,
B), whereas, the endogenous level of RNAPII was
decreased in all cell lines (Fig. 2A, C). A transcriptional
downregulation of RNAPII is the most plausible expla-
nation for the global gene suppression observed (Fig. 2F
and Supplementary Figs. S3–S5). This is consistent with a
previous study stating that a downregulation of POLR2A
encoding the major subunit of RNAPII was observed in
leukemic blasts following treatment with alvocidib, which
potently inhibits CDK955. A significant decrease in short
half-life MCL-1 at gene (Fig. 2G) and protein (Fig. 2A, D)
levels highlights a potential target inhibited by fadraciclib.
A rapid decrease in MCL-1 level perturbs a balance in
the BCL-2 family, activating the intrinsic apoptosis path-
way (Fig. 5B). AML cells are more dependent on MCL-1
than normal hematopoietic cells56, highlighting the
potential of fadraciclib as a therapeutic approach for
AML. Downregulation of E2F1 (Fig. 2G) may explain the
G1 cell cycle arrest seen in OCI-AML3 and MV4–11
following fadraciclib treatment (Supplementary Fig. S1).
Interestingly, Erk1/2 were suppressed in all cell lines
tested (Supplementary Fig. S2A, D), which potentially
promotes a reduction in MCL-1 stability and half-life57. In
various cancer cell lines, siRNA-mediated PPP1R10
knockdown results in tumor suppressor PTEN release
from nuclear sequestration58. Hence, the significant
decrease in PPP1R10 gene expression observed (Fig. 2G)
potentially promotes an induction of apoptosis. Using
leukemic blasts from adult patients with refractory AML
in a phase 1 clinical trial (NCT00470197), treatment with
the pan-CDKi alvocidib, resulted in a downregulation of
various genes55. Among these, downregulation of
POLR2A, encoding the major subunit of RNAPII, and
E2F1 was seen. In addition, a decrease in phosphorylation
of RNAPII and expression of MCL-1 was observed in
leukemia blasts of some patients treated with alvocidib
who achieved a CR59. Favorably, we found that the
function of CDK1, which plays an important role in
mitosis60,61, was not perturbed, suggesting better immune
function with less impact on normal hematopoietic cells
following fadraciclib treatment.
Recently, a phase 1 clinical trial of fadraciclib in solid
tumor patients was completed (NCT02552953)42. Dose-
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limiting toxicities were reversible and a biologically
effective dose of 192 mg/m2/day, which corresponds to
the drug concentration of 6–7 μM in vitro was
established42.
Over the past few years, many targeted therapies for
patients with AML have emerged with efficacy dependent
on molecular subtype of AML62. This highlights the
important of assessing the efficacy of fadraciclib on spe-
cific AML subtypes based on its mechanism of action of
inhibiting CDK9. As part of the Super Elongation Com-
plex (SEC), CDK9 is important for transcriptional elon-
gation, in particular in KMT2A-r AML63, it is therefore
rational to evaluate the efficacy of fadraciclib in this AML
subtype. Preliminary results indicate KMT2A-r AML cell
lines are more sensitive to fadraciclib29. Patient samples,
however, display a high diversity of genetic mutations
(Table. 1). We therefore observed a more variable fadra-
ciclib response with KMT2A-PTD status not being a
predictor for better treatment response. This is consistent
with previous results showing that the CDK9-specific
inhibitor atuveciclib inhibits the proliferation of seven
AML cell lines, regardless of KMT2A-r status64. In addi-
tion, atuveciclib displayed potent in vitro activity in 80%
of AML patient samples harboring KMT2A WT, includ-
ing those with mutant NPM1 or FLT3-ITD.
Considering the combination studies, primary AML
samples were selected based on the most common
favorable (e.g., NPM1) and unfavorable mutations (e.g.,
FLT3-ITD and KMT2A-PTD). Initially, we hypothesized
that the treatment response would be relevant to the risk
profiles of the individual genetic lesions in primary AML
samples. However, we found that complexity of the
molecular genetic lesions and karyotypes have more
influence. The more complex the molecular landscape,
the less efficacious the combination therapy (Supple-
mentary Table S4). The treatment response variability
associated with the high diversity of genetic mutations
observed reiterates the results of previous experiment
showing the variable fadraciclib response, regardless of
KMT2A-PTD status. Taken together, our results highlight
the importance of genetic and molecular profiling prior to
Fig. 5 A schematic diagram of the effects of fadraciclib at 4 h.
A Fadraciclib downregulates E2F1, resulting in cell cycle arrest at G1
phase. Downregulation of RNAPII is the most plausible explanation for
the global gene suppression observed. A rapid decrease in short half-
life MCL-1 level perturbs a balance in the BCL-2 family. A decrease in
the Erk1/2 activity observed in all cell lines tested potentially promotes
a reduction in MCL-1 stability and half-life. p38 MAPK is markedly
increased in MOLM-13 cell line only, implying that the stress response
and apoptosis are highly induced. B Fadraciclib downregulates MCL-1,
which activates the intrinsic apoptosis pathway, followed by cell
death. Indeed, a rapid decrease in MCL-1 level perturbs a balance in
the BCL-2 family, which leads directly to activator BH3-only proteins-
binding BAK and BAX, resulting in their homo-oligomerisation and
MOMP. Following this, pro-apoptotic proteins within the
mitochondrial intermembrane space, for example, Cyt c, DIABLO and
HTRA2 are released. Cyt c binds to APAF-1 to form the apoptosome.
Once formed, the apoptosome can then recruit and activate the
inactive pro-caspase-9. Following this, caspases-3, 6, and 7 are
activated and multiple proteolytic events occur. FAD, Fadraciclib; Cip/
Kip, cyclin-dependent kinase interacting protein/kinase inhibitory
protein; INK4, inhibitors of cyclin-dependent kinase 4; G1, Gap 1 phase;
S, Synthesis phase; G2, Gap 2 phase; M, Mitotic phase; BCL-2, B-cell
lymphoma 2; BCL-xL, B-cell lymphoma-extra large; BCL-w, B-cell
lymphoma 2-like protein 2; BAD, B-cell lymphoma 2-associated death
promoter; NOXA, phorbol-12-myristate-13-acetate-induced protein 1;
BIM, B-cell lymphoma 2-like protein 11; BID, BH3 interacting-domain
death agonist; PUMA, p53 upregulated modulator of apoptosis; BAK,
B-cell lymphoma 2 homologous antagonist/killer; BAX, B-cell
lymphoma 2-associated X protein; MOMP, mitochondrial outer
membrane permeabilisation; Cyt c, cytochrome c; DIABLO, direct
inhibitor of apoptosis proteins-binding protein with low pI; HTRA2,
high-temperature requirement A serine peptidase 2; APAF-1,
apoptotic protease activating factor-1; BIRC5, baculoviral inhibitor of
apoptosis repeat-containing 5; XIAP, X-linked inhibitor of apoptosis
protein.
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initiating therapy, to identify personalized therapeutic
combinations most likely to benefit individual patient.
Regarding the 2017 ELN risk stratification50, next gen-
eration sequencing (NGS), exome sequencing and gen-
ome wide assays65, are being developed to replace single
gene assays. This will facilitate better prognostication and
more personalized therapy in the future66. A short delay
in commencing therapy in newly diagnosed AML
had no effect on outcome after accounting for other
prognostic covariates67, providing a potential window to
perform NGS.
As a global effect, an increase in cell death in primary
human AML cells was shown for apoptosis, active
caspase-3 assays, and cell cycle analysis when fadraciclib
was combined with VEN, AraC, or AZA. In primary AML
cells, combining the MCL-1 inhibitor S63845 with VEN
results in greater efficacy than either inhibitor alone, with
a more potent activity against leukemic rather than nor-
mal hematopoietic progenitors68. In an AML patient-
derived xenograft mouse model bearing FLT3-ITD, the
CDK9 inhibitor A-1592668 combined with VEN provided
a significant survival advantage over single treatments69.
In a lymph node mimicking microenvironment, fadraci-
clib in combination with VEN for 24 h efficiently induced
apoptosis of primary CLL cells70, a disease where MCL-1
plays a role in disease progression and fludarabine resis-
tance71. Ongoing phase 1 clinical trials are evaluating the
safety and tolerability of fadraciclib in combination with
VEN in patients with relapsed/refractory AML or mye-
lodysplastic syndromes (MDS) (NCT04017546); and
relapsed/refractory CLL (NCT03739554).
When considering combining CDK9 inhibitors with
AraC, a recent phase 2 study (NCT01349972), demon-
strated a significantly higher efficacy of FLAM (alvocidib,
cytarabine plus mitoxantrone) as compared with the
standard “7+ 3” regimen in terms of a CR rate26,28.
However, no increase in overall or event-free survival
rates were observed. Potentially, this may be due to the
higher toxicity of the combination regimen based on our
preliminary data showing the impact of the fadraciclib+
AraC on normal hematopoietic cells.
In preliminary experiments, pre-treatment with alvoci-
dib reduced the IC50 of AZA in MV4–11 cell line72. In
the same manner seen in fadraciclib+AZA combination
presented here, alvocidib+AZA also increased %active
caspase-3 as compared with single treatments. In a
MOLM-13 xenograft model, the combination showed
greater tumor growth inhibition compared to single agent
treatments. Our results, demonstrated a potential ther-
apeutic window with the FAD2+AZA2 combination, as
measured by %Undivided %undivided of AML cells in cell
proliferation assay (Fig. 4C). These interesting results
identify an attractive therapeutic strategy warranting
consideration of clinical development in AML.
In summary, our studies indicate the preclinical efficacy
of the CDK2/9 inhibitor fadraciclib as a single agent or in
conjunction with frontline AML chemotherapeutics,
highlighting its potential as a novel therapeutic approach.
Our work implicates the importance of molecular genetic
profiling as a critical step prior to initiating therapy for
AML, highlighting the need for a more personalized
medicine approach to improve outcomes for patients.
Materials and methods
Cell lines and primary AML samples cell culture
OCI-AML3, MOLM-13, and MV4–11 (DSMZ) were
cultured at 37 °C in a 5% CO2 atmosphere in RPMI 1640
media (Sigma-Aldrich) with 20% or 10% fetal bovine
serum (Gibco), supplemented with 1 mM glutamine and
1% penicillin-streptomycin (Invitrogen).
Healthy donor and diagnostic primary AML samples
were taken in accordance with the Declaration of Hel-
sinki, and Ethics Committee approval (15/WS/0077).
Demographic data, cytogenetic abnormalities and genetic
lesions of AML patients are shown in Table. 1. Primary
samples were thawed and cultured overnight in serum-
free medium II (Stem Cell Technologies) supplemented
with hIL-3, hIL-6, hSCF, and hFLT3L (all at 10 ng/mL)
(Stem Cell Technologies).
Inhibitors
Ten micromolar stock solutions of fadraciclib (Cycla-
cel), AZA (Stratech), and VEN (Stratech) were prepared
in DMSO. 10mM AraC (Sigma-Aldrich) was prepared in
water. All stocks were stored at −20 °C and dilutions
freshly prepared in cell culture media.
Rezasurin reduction assay
Half-maximal inhibitory concentration (IC50) of AML
cell lines treated with fadraciclib for up to 72 h was
established using 7-Hydroxy-3H-phenoxazin-3-one-10-
oxide sodium salt resazurin assay (Sigma-Aldrich)
according to manufacturer’s instructions. IC50 were cal-
culated using GraphPad Prism 8 software (GraphPad
Software).
Gene expression analysis
RNA was extracted using RNA Easy Micro kits (Qiagen)
and converted to cDNA using high-capacity cDNA
reverse transcription kit (Applied Biosystems). Quantita-
tive reverse transcription polymerase chain reaction
(qRT-PCR) was performed using Fluidigm Biomark
technology and data were collected as per manufacturer’s
instructions. Data was analyzed using the 2−ΔΔCT com-
pared to no drug control (NDC) as previously described73.
Internal sample control was ensured by subtracting the
average of six housekeeping genes ATP5F1B, B2M, CYC1,
RNF20, TYW1, and UBE2D2 from the Ct value of each
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gene of interest. Mean and standard deviation of fold
change in expression were calculated. For Primer
sequences see Supplementary Table S1.
Protein extraction and quantification
In all, 1–5 × 106 cells were harvested and washed twice
in ice-cold PBS and pelleted at 300 × g for 5 min. Then,
the pellets were lyzed in ice-cold solubilization buffer
containing phosphatase and protease inhibitors at a con-
centration of 1 × 106 cells per 10 μl solubilization buffer
(50 mM Tris-HCl pH 7.5, 150mM NaCl, 1% Nonidet P40,
10% Glycerol, cOmplet ULTRA 1 tablet and PhosSTOP
phosphatase inhibitor 1 tablet per 10mL of solubilization
buffer). This suspension was left on ice and vortexed every
15min for 1 h, then centrifuged at 14,000 × g for 10 min to
pellet all cell debris. The supernatant was transferred to a
fresh eppendorf and stored at −80 o C until required.
Protein concentration was quantified using the Quick
Start Bradford Dye reagent and compared to a standard
curve prepared using Quick StartTM BSA protein. The
colorimetric protein assay was measured by visual
absorbance on the Spectramax M5 plate reader at 595 nm
at using SoftMax Pro software.
Protein analysis
Cell lysates were prepared and 30 µg of protein was
resolved. Western blotting was performed using the
NuPAGE electrophoresis system (Invitrogen) as per
manufacturer’s instructions, and protein detection via
Odyssey Fc Imaging System. Densitometry was performed
using Image Studio Lite version 5.2. Antibodies and
experimental conditions are outlined in Supplementary
Table S2.
Flow cytometry
For proliferation analysis, primary AML and normal
CD34+ cells were stained with CellTrace Violet (Thermo
Fisher Scientific) as per manufacturer’s protocol. For
establishing a maximum point of fluorescence staining,
cells were cultured with Colcemid (100 ng/mL, Sigma-
Aldrich) to determine non-dividing cells. All primary cells
were treated with fadraciclib, VEN, AraC, AZA or fadra-
ciclib in combination with VEN, AraC or AZA in phy-
siological growth factor conditions. Annexin V/7-
aminoactinomycin D (7-AAD) or DAPI (4’,6-diamidino-
2-phenylindole) (BD Biosciences) staining to assess
apoptosis by flow cytometry using 1 × 105 cells per con-
dition. Propidium iodide (PI) staining buffer to assess cell
cycle progression as per manufacturer’s protocol. Fixa-
tion/Permeabilization Solution Kit (BD Biosciences) was
used prior to MCL-1 or active caspase-3 staining. For
staining reagents used, see Supplementary Table S3.
Combination studies
CompuSyn software (ComboSyn, Inc) was used to
investigate the synergism in the cell proliferation assays.
The software was based on the Chou-Talalay method for
drug combination based on the median-effect equation
derived from the mass-action law principle74. The CI
provides a quantitative definition for additive effect (CI=
1), synergism (CI < 1) or antagonism (CI > 1) in drug
combinations.
Statistics
Average responses from at least three independent
experiments are shown (mean ± SD). Statistical analysis
used GraphPad Prism 8 for Student’s t-test and one-way
ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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